Eukles Asset Management trimmed its position in shares of Chemed Co. (NYSE:CHE – Free Report) by 5.6% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 6,191 shares of the company’s stock after selling 366 shares during the period. Chemed makes up 1.4% of Eukles Asset Management’s portfolio, making the stock its 25th biggest position. Eukles Asset Management’s holdings in Chemed were worth $3,280,000 at the end of the most recent quarter.
Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Creative Planning boosted its position in Chemed by 2.8% in the 2nd quarter. Creative Planning now owns 1,228 shares of the company’s stock valued at $667,000 after buying an additional 34 shares during the last quarter. Park Avenue Securities LLC acquired a new position in shares of Chemed in the third quarter worth about $260,000. GAMMA Investing LLC boosted its holdings in Chemed by 60.5% in the third quarter. GAMMA Investing LLC now owns 138 shares of the company’s stock valued at $83,000 after purchasing an additional 52 shares during the last quarter. CWM LLC grew its stake in Chemed by 22.2% during the 3rd quarter. CWM LLC now owns 485 shares of the company’s stock valued at $291,000 after purchasing an additional 88 shares in the last quarter. Finally, Inspire Investing LLC increased its holdings in Chemed by 5.6% during the 3rd quarter. Inspire Investing LLC now owns 5,409 shares of the company’s stock worth $3,251,000 after purchasing an additional 288 shares during the last quarter. Hedge funds and other institutional investors own 95.85% of the company’s stock.
Chemed Stock Down 0.6 %
Shares of NYSE CHE opened at $550.53 on Monday. The stock’s 50 day moving average price is $543.17 and its two-hundred day moving average price is $564.72. Chemed Co. has a 52-week low of $512.12 and a 52-week high of $654.62. The stock has a market capitalization of $8.29 billion, a P/E ratio of 27.82, a PEG ratio of 2.16 and a beta of 0.48.
Insider Activity
Wall Street Analysts Forecast Growth
Several research firms have recently commented on CHE. Royal Bank of Canada reduced their target price on Chemed from $697.00 to $633.00 and set an “outperform” rating for the company in a research note on Tuesday, November 5th. StockNews.com upgraded shares of Chemed from a “hold” rating to a “buy” rating in a research note on Saturday, November 30th.
Read Our Latest Research Report on Chemed
Chemed Profile
Chemed Corporation provides hospice and palliative care services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers primarily in the United States. The company operates in VITAS and Roto-Rooter segments. It offers plumbing, drain cleaning, excavation, water restoration, and other related services to residential and commercial customers through company-owned branches, independent contractors, and franchisees.
Read More
- Five stocks we like better than Chemed
- 3 Dividend Kings To Consider
- 2 Defensive Energy Stocks to Hedge Against Trade Turmoil
- 3 Healthcare Dividend Stocks to Buy
- 3 Mining Stocks Poised to Ride the Precious Metals Boom
- Roth IRA Calculator: Calculate Your Potential Returns
- Cybersecurity Stocks Are Soaring—Here’s Why These 3 Stand Out
Want to see what other hedge funds are holding CHE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Chemed Co. (NYSE:CHE – Free Report).
Receive News & Ratings for Chemed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemed and related companies with MarketBeat.com's FREE daily email newsletter.